Bladder Cancer Immunotherapy Avoids Removal
A clinical study has shown that the new immunotherapy treatment using the drug "Cretostimogen Greenadynoribevic" allows patients with high-risk bladder cancer to avoid surgical removal of the bladder. Specifically, 81% of patients were able to retain their bladders for more than two years, with complete remission in 75% of them and sustained responses in about 60%. The treatment yielded promising results with mild side effects and helps improve patients' quality of life by reducing the need for major surgery.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)